Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons

Pardeike, Jana; Weber, Sabrina; Zarfl, Hans Peter; Pagitz, Maximilian; Zimmer, Andreas

doi:10.1016/j.ejpb.2016.07.018

Cited by 54 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also nanoparticles can achieve higher bioavailability for systemic delivery purposes. Lipid nanoparticles used in lung drug delivery, like other routes of administration, have the advantage of sustained drug delivery( 103 114 117 118 ). Some of the most important advantages and limitations of this route of administration are listed in Table 6 .…”

Section: Lipid Nanoparticles Applications and Different Routes Of Admmentioning

confidence: 99%

Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages

2018

View full text Add to dashboard Cite

During the recent years, more attentions have been focused on lipid base drug delivery system to overcome some limitations of conventional formulations. Among these delivery systems solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are promising delivery systems due to the ease of manufacturing processes, scale up capability, biocompatibility, and also biodegradability of formulation constituents and many other advantages which could be related to specific route of administration or nature of the materials are to be loaded to these delivery systems. The aim of this article is to review the advantages and limitations of these delivery systems based on the route of administration and to emphasis the effectiveness of such formulations.

show abstract

Section: Lipid Nanoparticles Applications and Different Routes Of Admmentioning

confidence: 99%

Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages

2018

View full text Add to dashboard Cite

show abstract

“…Clinically, the first signs include breathing difficulties and wheezing due to the obstruction of airways by fungal granulomata ( Girma et al, 2016 ). Subsequently general symptoms such as lethargy, inappetence, diarrhea, and feather ruffling may appear ( Pardeike et al, 2016 ). In other cases, wasting may be the only symptom ( Neumann, 2016 ).…”

Section: Veterinary Infections Caused By Aspergillus mentioning

confidence: 99%

“…Moreover, the fungus’ sequestration from the blood stream may result in it not being exposed to the drug ( Girma et al, 2016 ). Consequently, oral antimycotics are preferred and various approaches such as nebulization or the use of nanosuspensions have been attempted ( Wlaź et al, 2015 ; Pardeike et al, 2016 ). Since therapeutic protocols have not been validated specifically for birds in general and for the various species in particular, necessary care should be taken, especially considering the prolonged time required to complete the treatment ( Tartor and Hassan, 2017 ).…”

Section: Veterinary Infections Caused By Aspergillus mentioning

confidence: 99%

Diagnostic Aspects of Veterinary and Human Aspergillosis

Elad

Segal

2018

Front. Microbiol.

View full text Add to dashboard Cite

The genus Aspergillus is composed of more than 300 species, a fraction of which are involved in animal or human infections mostly following environmental exposure. Various risk factors (i.e., immunosuppression, tuberculosis) have been recognized for human whereas for veterinary infections, unhygienic management, trauma, anatomical conformation of the skull, or suspected immunological deficiencies have been suggested. In animals, aspergillosis is mostly sporadic but in some circumstance such as infections on poultry farms may involve the whole flock. Since the high prevalence of immunosuppression in human patients has not been mirrored in veterinary medicine, and although to the best of our knowledge, no comprehensive data on the prevalence of aspergillosis in animals has been published, their epidemiology has not changed during the last decades. The impact of these infections may be economic or if they are incurable, sentimental. The objective of the first part is to describe the diagnosis of the main clinical entities caused by Aspergillus spp. in animals. It includes disseminated canine aspergillosis, canine and feline sino-nasal and sino-orbital aspergillosis, guttural pouch mycosis in horses, mycotic abortion in cattle, mycotic keratitis in horses, and avian aspergillosis. When pathogenesis and clinical aspects are relevant for diagnosis—they will be addressed as well. The second part deals with human aspergillosis, which is a multifaceted disease, manifested in a spectrum of clinical entities affecting one or more organs. Diagnosis is based on the clinical manifestation, supported and confirmed by laboratory means, involving the classical approach of demonstrating the etiological agent in the clinical specimens and in culture. Noncultural methods, such as antigen detection and/or molecular assays to detect fungal nucleic acids or protein profiles, are used as well. The isolation and identification of the fungus allows the determination of its susceptibility to antifungal drugs. Thus, antifungal susceptibility testing maybe considered as part of the diagnostic process, which is of relevance for management of the infection. In this review article, the part dealing with diagnostic aspects of aspergillosis in humans concentrates on susceptibility testing of Aspergillus spp. to antifungal drugs and drug combinations. The technologies and methods of susceptibility testing are described and evaluated.

show abstract

“…Furthermore, the survival rates of the group of mice receiving nebulized itraconazole were significantly higher than those of the group of mice receiving oral itraconazole administration ( 20 ). Since those reports, new formulations of itraconazole for topical treatment, such as nanoparticles ( 21 , 22 ), polymeric micelles ( 23 ), itraconazole-loaded nanostructured lipid carriers ( 24 ), and dry powder ( 25 ), have been developed, although the in vivo antifungal activities of these inhaled products have not been reported formally. It is worth noting that inhaled PUR1900 (iSPERSE-formulated itraconazole; Pulmatrix), being developed for fungal infection in patients with cystic fibrosis, was recently reported to demonstrate higher lung exposure and lower systemic exposure than oral dosing in rats ( 26 ).…”

Section: Introductionmentioning

confidence: 99%

In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice

Kimura

Nakaoki

Colley³

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

PC945 is a novel triazole optimized for lung delivery, and the objective of this study is to determine the effects of intranasally dosed PC945 on Aspergillus fumigatus infection and associated biomarkers in immunocompromised mice. PC945, posaconazole, or voriconazole was administered intranasally once daily on days 0 to 3 (early intervention) or days 1 to 3 (late intervention) postinfection in temporarily neutropenic A/J mice infected intranasally with A. fumigatus, and bronchoalveolar lavage fluid (BALF) and serum were collected on day 3. The effects of extended prophylaxis treatment (daily from days −7 to +3 or days −7 to 0) were also compared with those of the shorter treatment regimens (days −1 to +3 or days −1 and 0). Early and late interventions with PC945 (2.8 to 350 μg/mouse; approximately 0.11 to ∼14 mg/kg of body weight) were found to inhibit lung fungal loads and to decrease the concentrations of galactomannan (GM) in both BALF and serum as well as several biomarkers in BALF (interferon gamma [IFN-γ], interleukin-17 [IL-17], and malondialdehyde) and serum (tumor necrosis factor alpha [TNF-α] and IL-6) in a dose-dependent manner and were >3- and >47-fold more potent than intranasally dosed posaconazole and voriconazole, respectively. Furthermore, extended prophylaxis with low-dose PC945 (0.56 μg/mouse; 0.022 mg/kg) was found to inhibit fungal loads and to decrease the concentrations biomarkers more potently than did the shorter treatment regimens. Thus, PC945 dosed intranasally once daily showed potent antifungal effects, and the effects of PC945 accumulated upon repeat dosing and were persistent. Therefore, PC945 has the potential to be a novel inhaled therapy for the treatment of A. fumigatus infection in humans.

show abstract

Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons

Cited by 54 publications

References 30 publications

Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages

Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages

Diagnostic Aspects of Veterinary and Human Aspergillosis

In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice

Contact Info

Product

Resources

About